Prodrug Strategy for PROTACs: High Efficiency and Low Toxicity

Prodrug Strategy for PROTACs: High Efficiency and Low Toxicity

Saved in:

Bibliographic Details
Main Authors:	Yuqing Li, Yongcheng Guo, Simin Ma, Baobang Long, Rui Kong, Xin Huang, Kun Zhao, Ying Zhi
Format:	Article
Language:	English
Published:	American Chemical Society 2025-06-01
Series:	ACS Omega
Online Access:	https://doi.org/10.1021/acsomega.5c01241
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PROTACs: Mechanism and Bioavailability enhancement strategies by nanotechnology, RNA viral infections (vaccine strategy) and Prodrug development
by: Sanaul Mustafa, et al.
Published: (2025-01-01)

PROTACs: Mechanism and Bioavailability enhancement strategies by nanotechnology, RNA viral infections (vaccine strategy) and Prodrug development
by: Sanaul Mustafa, et al.
Published: (2025-01-01)

Advancing Design Strategy of PROTACs for Cancer Therapy
by: Hang Luo, et al.
Published: (2025-07-01)

Computational strategies for PROTAC drug discovery
by: Jia Wu, et al.
Published: (2023-01-01)

Molecular features defining the efficiency of bioPROTACs
by: Dorothea Winkelvoß, et al.
Published: (2025-06-01)

Linker-free PROTACs efficiently induce the degradation of oncoproteins
by: Jianchao Zhang, et al.
Published: (2025-05-01)

PROTACs improve selectivity for targeted proteins
by: Lihua Liu, et al.
Published: (2025-04-01)

Application of PROTACs in target identification and validation
by: Yang Liu, et al.
Published: (2024-02-01)

The Peptide PROTAC Modality: A New Strategy for Drug Discovery
by: Youmin Zhu, et al.
Published: (2025-04-01)

TrypPROTACs Unlocking New Therapeutic Strategies for Chagas Disease
by: Ana Luísa Rodriguez Gini, et al.
Published: (2025-06-01)

Creation of anthracycline prodrug
by: A. N. Tevyashova
Published: (2014-12-01)

PROTACs targeting epigenetic proteins
by: Chao Zhang, et al.
Published: (2023-11-01)

PROTAC technology for prostate cancer treatment
by: Zhen Wang, et al.
Published: (2025-01-01)

MEGA PROTAC, MEGA DOCK-based PROTAC mediated ternary complex formation pipeline with sequential filtering and rank aggregation
by: Sadettin Y. Ugurlu, et al.
Published: (2025-02-01)

PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation
by: Endry Wahyu Syahputra, et al.
Published: (2025-04-01)

Corrigendum to: PROTAC technology for prostate cancer treatment
by: Zhen Wang, et al.
Published: (2025-07-01)

Modeling PROTAC degradation activity with machine learning
by: Stefano Ribes, et al.
Published: (2024-12-01)

Current Trends in Clinical Trials of Prodrugs
by: Diogo Boreski, et al.
Published: (2025-02-01)

PROTACs for BRDs proteins in cancer therapy: a review
by: Chao Wang, et al.
Published: (2022-12-01)

Structure-Based Design of “Head-to-Tail” Macrocyclic PROTACs
by: Chungen Li, et al.
Published: (2024-11-01)

PROTAC Technology as a New Tool for Modern Pharmacotherapy
by: Natalia Kubryń, et al.
Published: (2025-05-01)

Design and Synthesis of Sustain-Acting Melatonin Prodrugs
by: Phạm Văn Thoại, et al.
Published: (2013-01-01)

Dimensionless parameter predicts bacterial prodrug success
by: Brandon Alexander Holt, et al.
Published: (2022-01-01)

Smart stimuli-responsive carrier-free nanoassembly of SN38 prodrug as efficient chemotherapeutic nanomedicine
by: Guanting Li, et al.
Published: (2023-01-01)

Decoy-PROTAC for specific degradation of “Undruggable” STAT3 transcription factor
by: Shiqing Li, et al.
Published: (2025-03-01)

Single atom engineering for radiotherapy-activated immune agonist prodrugs
by: Zexuan Ding, et al.
Published: (2025-07-01)

Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress
by: Jing Chen, et al.
Published: (2025-09-01)

Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer
by: Zhao K, et al.
Published: (2025-06-01)

FDA-approved kinase inhibitors in PROTAC design, development and synthesis
by: Kacper Kossakowski, et al.
Published: (2025-12-01)

Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs
by: André T. S. Vicente, et al.
Published: (2025-07-01)

Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues
by: Hany E. Marei, et al.
Published: (2025-06-01)

PROTAC-induced protein structural dynamics in targeted protein degradation
by: Kingsley Y Wu, et al.
Published: (2025-02-01)

Oligonucleotide-based PROTACs to Degrade RNA- and DNA-Binding Proteins
by: Céline N. Weller, et al.
Published: (2025-03-01)

Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration
by: Sol Jeong, et al.
Published: (2025-05-01)

Synthesis and Herbicidal Assessment of 3‑Acyltetramic Acid Prodrugs
by: Simon Backx, et al.
Published: (2025-07-01)

Correction: Decoy-PROTAC for specific degradation of “Undruggable” STAT3 transcription factor
by: Shiqing Li, et al.
Published: (2025-07-01)

Targeting Stat3 with conditional knockout or PROTAC technology alleviates renal injury by Limiting pyroptosisResearch in context
by: Ming-lu Ji, et al.
Published: (2025-06-01)

A self‐reinforced activatable photosensitizer prodrug enabling synergistic photodynamic and chemotherapy
by: Daipeng Huang, et al.
Published: (2024-12-01)

Design and development of PROTACs: A new paradigm in anticancer drug discovery
by: Vishal Mathur, et al.
Published: (2025-09-01)

PROTAC<sup>®</sup> technology and potential for its application in infection control
by: M. A. Zakharova, et al.
Published: (2024-07-01)